Thus, there is a need to consider how NK cells respond to IL-15 and how tumor-localized production of IL-15 (or IL-2, IL-21, or IL-10) is affected by therapeutics and how this therapy can be customized to address the likely insufficient cytokine receptor agonism within the TME. The gene discussed is IL21; the disease is neoplasm.